| Product roll-outs, which began this year, by specialty pharmaceutical company iX Biopharma have met with success after success. The latest is its Xativa™, launched in Australia two months ago (end-April 2020). Initial production runs of approximately 1,700 boxes of Xativa™, a sublingual medicinal cannabidiol (“CBD”) wafer, have been fully sold, said the company. CBD, one of the primary non-psychoactive compounds found in the cannabis plant, has attracted growing interest in recent times due to its safety and effectiveness in treating a vast spectrum of human health issues. Watch TV news coverage of XativaTM |
Read about earlier rollouts:
|
» iX BIOPHARMA: Sold more than 4,500 boxes of ED products through telemedicine |
| iX Biopharma said doctors and patients "acknowledge that Xativa™ differentiates from other commonly available products (mainly flowers, oils and oral capsules) as it has valuable features such as fixed unit dosing, improved speed and level of absorption, as well as predictability of effect." |
Xativa™ is expected to be a superior alternative for certain population segments including the young and senior citizens, as it is easy to use and avoids the need to swallow capsules or ingest oils which may be more difficult to tolerate.
Its launch was covered by an Australian national news network, Nine News, which helped to raise awareness of the benefits of Xativa™ and the WaferiX sublingual delivery technology.
While the medicinal benefits of CBD are recognised, most delivery forms available today suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability to truly provide an effective therapeutic effect for users.
Leveraging on iX Biopharma’s novel and patented WaferiX™ technology, the company has developed Xativa™ to address this gap in the market.
Manufactured via iX Biopharma’s proprietary freeze-drying technique, the WaferiX™ matrix holding the active CBD molecules is designed to transport drug actives rapidly across the sublingual membrane into the blood vessels for rapid absorption and faster therapeutic action.
Furthermore, Xativa™ offers a fixed unit dose that is familiar to physicians, facilitating standardised prescription and precise dosing, said iX Biopharma.
 Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma, said: “We are very encouraged by the interest and demand garnered for true sublingual cannabis wafers. The early enthusiastic response from both patients and doctors gives us confidence that WaferiX™ based sublingual cannabis wafers provides a strong value proposition when compared to existing products in the market.” |
